Immune cell networking in solid tumors: focus on macrophages and neutrophils

Front Immunol. 2024 Feb 14:15:1341390. doi: 10.3389/fimmu.2024.1341390. eCollection 2024.

Abstract

The tumor microenvironment is composed of tumor cells, stromal cells and leukocytes, including innate and adaptive immune cells, and represents an ecological niche that regulates tumor development and progression. In general, inflammatory cells are considered to contribute to tumor progression through various mechanisms, including the formation of an immunosuppressive microenvironment. Macrophages and neutrophils are important components of the tumor microenvironment and can act as a double-edged sword, promoting or inhibiting the development of the tumor. Targeting of the immune system is emerging as an important therapeutic strategy for cancer patients. However, the efficacy of the various immunotherapies available is still limited. Given the crucial importance of the crosstalk between macrophages and neutrophils and other immune cells in the formation of the anti-tumor immune response, targeting these interactions may represent a promising therapeutic approach against cancer. Here we will review the current knowledge of the role played by macrophages and neutrophils in cancer, focusing on their interaction with other immune cells.

Keywords: anti-tumor immunity; immune cell network; tumor microenvironment; tumor-associated macrophages; tumor-associated neutrophils.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunity
  • Immunotherapy
  • Macrophages
  • Neoplasms*
  • Neutrophils*
  • Tumor Microenvironment

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SC is recipient of a fellowship from the Italian Association for Cancer Research. ID is financed by the HIgh Profile POst doc program – HIPPO Fondi 5x1000 Italian Ministry of University and Research. The Italian Ministry of Health GR-2018-12365588 and RF-2021-12372202 to SJ, the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS - PNRR-MAD-2022-12375947 to SJ, the Italian Association for Cancer Research AIRC IG-22815 to SJ; Italian Ministry of University and Research - PRIN 2017K7FSYB to SJ, are gratefully acknowledged.